Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: QVAR 40

« Back to Dashboard
Qvar 40 is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug.

This drug has forty-nine patent family members in eighteen countries.

The generic ingredient in QVAR 40 is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

Summary for Tradename: QVAR 40

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list14

Pharmacology for Tradename: QVAR 40

Clinical Trials for: QVAR 40

Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)
Status: Completed Condition: Asthma

Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
Status: Completed Condition: Asthma

Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications
Status: Completed Condition: Asthma; Obesity

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
Status: Recruiting Condition: Asthma; Allergic Rhinitis

Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis
Status: Active, not recruiting Condition: Asthma; Asthmatic Crisis

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
Status: Completed Condition: Seasonal Allergic Rhinitis; SAR

Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma
Status: Completed Condition: Asthma

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
Status: Completed Condition: Seasonal Allergic Rhinitis; Hayfever

A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults
Status: Completed Condition: Pharmacokinetics

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)
Status: Completed Condition: Allergic Rhinitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm
QVAR 40
beclomethasone dipropionate
AEROSOL, METERED;INHALATION020911-002Sep 15, 2000RXYes5,776,432<disabled>Y<disabled>
Teva Branded Pharm
QVAR 40
beclomethasone dipropionate
AEROSOL, METERED;INHALATION020911-002Sep 15, 2000RXYes5,683,677<disabled>Y<disabled>
Teva Branded Pharm
QVAR 40
beclomethasone dipropionate
AEROSOL, METERED;INHALATION020911-002Sep 15, 2000RXYes6,446,627<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: QVAR 40

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,681,545 Medicinal aerosol formulations<disabled in preview>
5,766,573 Medicinal aerosol formulations<disabled in preview>
5,720,940 Medicinal aerosol formulations<disabled in preview>
6,346,232 Method of forming conductive lines<disabled in preview>
5,776,434 Medicinal aerosol formulations<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: QVAR 40

Country Document Number Publication Date
New Zealand240237Jun 27, 1994
European Patent Office0372777Nov 22, 1990
Canada2094266Jun 01, 1999
European Patent Office0995434Nov 26, 2003
Canada2303601Jun 06, 1990
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc